Recent Publications
Paolo De Simone, Renato Romagnoli, Francesco Tandoi, Paola Carrai, Giorgio Ercolani, Eugenia Peri, Fausto Zamboni, Laura Mameli, Fabrizio Di Benedetto, Umberto Cillo, Luciano De Carlis, Andrea Lauterio, Luigi Lupo, Giuseppe Tisone, Martin Prieto, Carmelo Loinaz, Antoni Mas, Abid Suddle, David Mutimer, Bruno Roche, Andrea Wartenberg-Demand, Gabriele Niemann, Heike Böhm, Didier Samuel. Early introduction of subcutaneous hepatitis B immunoglobulin following liver transplantation for hepatitis B virus infection: A prospective, multicenter study. Transplantation (in press).
Xavier Forns, Didier Samuel, David Mutimer, Stefano Fagiuoli, Miquel Navasa, Kosh Agarwal, Marina Berenguer, Massimo Colombo, Kerstin Herzer, Frederik Nevens, Bjorn Daems, Katrien Janssen, Sivi Ouwerkerk-Mahadevan, Holly Kimko, Erkki Lathouwers, James Witek, Rodica Van Solingen-Ristea. Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C. Annals of Hepatology (in press).
Rajoriya N, Leithead JA, Elsharkawy AM, Gunson BK, Perera TM, Mutimer D. The impact of the UKELD score on outcomes of patients listed for late hepatic artery thrombosis. Liver Transpl. 2015 Oct 19. doi: 10.1002/lt.24358. [Epub ahead of print]
Kelly C, Swadling L, Capone S, Brown A, Richardson R, Halliday J, von Delft A, Oo Y, Mutimer D, Kurioka A, Hartnell F, Collier J, Ammendola V, Del Sorbo M, Grazioli F, Luisa Esposito M, Di Marco S, Siani L, Traboni C, Hill AV, Colloca S, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E. Chronic Hepatitis C Virus infection subverts vaccine induced T-cell immunity in humans. Hepatology. 2015 Oct 16. doi: 10.1002/hep.28294. [Epub ahead of print]
Rowe IA, Tully DC, Armstrong MJ, Parker R, Guo K, Barton D, Morse GD, Venuto CS, Ogilvie CB, Hedegaard DL, McKelvy JF, Wong-Staal F, Allen TM, Balfe P, McKeating JA, Mutimer DJ. Effect of scavenger receptor BI antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.
Liver Transpl. 2015 Oct 5. doi: 10.1002/lt.24349. [Epub ahead of print]
Krishnamoorthy TL, Mutimer D. Hepatitis B: encouraging the use of interferon. Curr Opin Infect Dis. 2015 Dec;28(6):557-62.
Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu SJ, Buggisch P, Samuel D, Mutimer D, Nault B, Merz M, Bao W, Griffel LH, Brass C, Naoumov NV; ESSENTIAL II Study Group. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther. 2015 Oct;42(7):829-44. doi: 10.1111/apt.13342. Epub 2015 Aug 4.
Li KK, Trivedi PJ, Von Heimendahl S, Bruns T, Ward ST, Oo Y, Mutimer D. Hepatocellular carcinoma surveillance in hepatitis B virus-infected individuals: Who and how? Hepatology. 2015 Jun 4. doi: 10.1002/hep.27924. [Epub ahead of print].
Lim TR, Mutimer DJ. The association of hepatitis C virus infection and post-liver transplant diabetes. Aliment Pharmacol Ther. 2015 Mar;41(5):488.
Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Reijnders JG, Oo Y, Petersen J, van Bömmel F, de Knegt RJ, Santantonio T, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen B, Janssen HL; VIRGIL Surveillance Study Group. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015 Aug;64(8):1289-95.
Mutimer D. Ribavirin with interferon for hepatitis C in dialysis patients: efficacious and safe in the right patients in good hands. Gut. 2015 Feb;64(2):190-1.
Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R; VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014 May 22;370(21):1993-2001.
Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014 May 15;370(20):1889-98.
Wilkins E, Nelson M, Agarwal K, Awoyemi D, Barnes E, Bhagani S, Brook G, Brown A, Castelino S, Cooke G, Fisher M, Geretti AM, James R, Kulasegaram R, Leen C, Mutimer D, Orkin C, Page E, Palfreeman A, Papineni P, Rodger A, Tong CY; British HIV Association. British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Med. 2013 Nov;14 Suppl 4:1-71.
Levy G, Villamil FG, Nevens F, Metselaar HJ, Clavien PA, Klintmalm G, Jones R, Migliaccio M, Prestele H, Orsenigo R; REFINE Study Group. REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. Am J Transplant. 2014 Mar;14(3):635-46.
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. European Association for Study of Liver. J Hepatol. 2014 Feb;60(2):392-420.
Lim TR, Tan BH, Mutimer DJ. Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection. Int J Antimicrob Agents. 2014 Jan;43(1):17-25.
Rowe IA, Parker R, Armstrong MJ, King AL, Houlihan DD, Mutimer DJ. Improving the quality of clinical practice guidelines for clinicians and patients. Hepatology. 2014 May;59(5):2055-6.
View all publications in research portal